Skip to main content
PMC home page
Evidence-based Complementary and Alternative Medicine : eCAM logoLink to Evidence-based Complementary and Alternative Medicine : eCAM
. 2013 May 25;2013:265061. doi: 10.1155/2013/265061

Tetrandrine Suppresses Cancer Angiogenesis and Metastasis in 4T1 Tumor Bearing Mice

Jian-Li Gao 1,*, Xing Ji 1, Tong-Chuan He 2, Qi Zhang 3, Kai He 4, Yan Zhao 1, Su-Hong Chen 3, Gui-Yuan Lv 1,*
PMCID: PMC3677646  PMID: 23762115

Abstract

Metastasis remains the most deadly aspect of cancer and still evades direct treatment. Thus, there is a great need to develop new treatment regimens to suppress tumor cells that have escaped surgical removal or that may have already disseminated. We have found that tetrandrine (TET) exhibits anticolon cancer activity. Here, we investigate the inhibition effect of TET to breast cancer metastasis, angiogenesis and its molecular basis underlying TET's anticancer activity. We compare TET with chemotherapy drug doxorubicin in 4T1 tumor bearing BALB/c mice model and find that TET exhibits an anticancer metastatic and antiangiogenic activities better than those of doxorubicin. The lung metastatic sites were decreased by TET, which is confirmed by bioluminescence imaging in vivo. On the other hand, laser doppler perfusion imaging (LDI) was used for measuring the blood flow of tumor in 4T1-tumor bearing mice. As a result, the local blood perfusion of tumor was markedly decreased by TET after 3 weeks. Mechanistically, TET treatment leads to a decrease in p-ERK level and an increase in NF-κB levels in HUVECs. TET also regulated metastatic and angiogenic related proteins, including vascular endothelial growth factor, hypoxia-inducible factor-1α, integrin β5, endothelial cell specific molecule-1, and intercellular adhesion molecule-1 in vivo.

1. Introduction

Tetrandrine (TET), a bisbenzylisoquinoline alkaloid isolated from the dried root of Stephania tetrandra (or hang fang ji) of the Menispermaceae, is a bioactive alkaloid with a molecular weight of 622.76 g/mol. Many reports indicated that TET exhibits very broad pharmacological actions, including immunomodulating, antihepatofibrogenetic, antiinflammatory, antiarrhythmic, antiportal hypertension, anticancer, and neuroprotective activities [1]. The beneficial effects of TET on tumor cell cytotoxicity and radiosensitization, multidrug resistance, normal tissue radioprotection, and angiogenesis are most promising and deserve great attention [2, 3]. Several investigations indicated that TET generally presents its anticancer effects in the micromolar concentrations on clone, leukemia, bladder, hepatoma, and lung cancer in vitro [4–8].

In our previous research, we have found that TET exhibits significant anticancer activity in colon cancer line HCT116. Mechanistically, the inhibitory effect of TET on colon cancer cells may be at least in part mediated by targeting β-catenin activity, and the sensitivity of cancer cells to TET may be determined by the functional status of β-catenin [9].

Nevertheless, with the development of clinical surgical treatment, the growth of primary tumor was no longer the critical element influencing the overall survival in cancer patients. Prevention of metastasis and more effective treatment of cancer metastasis are necessary for cancer therapy. Thus, antimetastasis therapy that targets tumor cells escaped surgical removal or already disseminated, and tumor angiogenic process has a better chance of success. Although several rational lines of evidence support the application of TET as an anticancer metastatic agent [10], the cellular mechanisms underlying the antiangiogenic and antimetastatic effects of TET activation in tumor cells remain elusive.

In this study, we use a mouse model for stage IV breast cancer (4T1 tumor bearing BALB/c mice model) for evaluating the antimetastatic effect of TET in lower concentration (10 mg/kg/d, which could not change the growth of tumor mass). Meanwhile, laser Doppler imager (LDI) was used for measuring blood perfusion of the tumor bearing area, which could measure the local blood flow and vascular network and reflect the angiogenic activity of the tumor bearing mice indirectly. Our results show that TET could significantly inhibit endothelial cell (EC) proliferation, adhesion, migration, invasion, and tube formation by targeting angiogenic factors, namely vascular endothelial growth factor (VEGF) and hypoxia-Inducible factor-1α (HIF-1α), as well as adhesion factors, such as integrin β5, endothelial cell specific molecule-1 (ESM-1), and intercellular adhesion molecule-1 (ICAM-1), and by interfering with the ERK pathway, leading to the suppression of tumor metastasis and tumor angiogenesis.

2. Materials and Methods

2.1. Cell Culture and Animals

Mouse breast cancer 4T1 and HEK-293 cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and grown in the DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS (Hyclone, Logan, UT, USA) and 50 U penicillin/streptomycin. Human umbilical vein endothelial cell line (HUVEC) was immortalized as described in [11] and maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 15% FBS, 2 mM L-glutamate, 100 U/mL penicillin and 100 μg/mL streptomycin. All cells were cultured at 37°C in a 5% CO2 incubator.

Female BALB/c mice (4-5 weeks old) were purchased from Shanghai Lab. Animal Research Center and maintained at the animal facility of Experimental Animal Research Center of Zhejiang Chinese Medical University. All procedures were performed according to protocols following the guidelines for the Use and Care of Laboratory Animals published by the US National Institutes of Health (NIH Publication no. 85–23, revised 1996).

2.2. Chemicals and Drug Preparations

TET and doxorubicin (Dox) were purchased from Sigma-Aldrich (St. Louis, MO, USA). These compounds were dissolved in DMSO to make stock solutions and were kept at −20°C as aliquots. The solution was diluted with Milli-Q water into 2 mg/mL and ultrasonificated into a fine suspension before in vivo use. 0.1% DMSO was used in vehicle group in in vitro assays.

2.3. Establishment of Stably Tagged 4T1-Luc Cell Lines

The 4T1 cells were stably transduced with firefly luciferase by using a retroviral vector expressing firefly luciferase as described in [12]. Briefly, recombinant retrovirus was packaged in HEK-293 cells by cotransfecting cells with pSEB-Luc and pAmpho packaging plasmid using LipofectAMINE (Invitrogen). Pooled stable cells were selected with blasticidin S (6 μg/mL) for 7 days. The firefly luciferase activity was confirmed by using Promega's Luciferase Assay kit (Promega, Madison, WI, USA).

2.4. MTT Proliferation Assay

A modified MTT assay was used to examine the cell proliferation as described in [13]. Briefly, iHUVEC (1 × 104 cells/well, 50–70% density) cells were seeded in 96-well plates. Drugs were added to the cells at variable concentrations or solvent control (0.1% DMSO). At 48 h after treatment, 15 μL MTT dye solution was added to each well and incubated for additional 4 h. Subsequently, the cell culture medium was removed, and 100 μL/well DMSO was added to dissolve formazan crystals in a humidified atmosphere overnight. Absorbance at 570 nm was measured using a 96-well microplate reader.

2.5. Crystal Violet Viability Assay

Crystal violet assay was conducted as described in [14]. Experimentally, iHUVEC cells were treated with drugs. At 24 h after treatment, cells were carefully washed with PBS and stained with 0.5% crystal violet formalin solution at room temperature for 20–30 min. The stained cells were washed with tape water and air-dried for taking macrographic images. For quantitative measurement, the stained cells were dissolved in 10% acetic acid (1 mL per well for 12-well plate) at room temperature for 20 min with shaking. Absorbance at 570–590 nm was measured.

2.6. Cell Adhesion Assay

For the cell adhesion model, HUVECs and 4T1 cells were used to study the adhesive ability between two different kinds of cell types. Briefly, HUVECs (2 × 104 each well) were grown to confluence on fibronectin-coated wells of 96-well plates. The plates were blocked with Hank's balanced salt solution (HBSS) containing 1% bovine serum albumin (BSA) (HBSS-BSA) for 30 min before the adhesion assay. BSA-coated wells serve as a negative control.

The 4T1 cells were trypsinized and suspended in HBSS-BSA and then labeled with 10 μL Hoechst 33258 for 30 min at 37°C followed by washing with HBSS-BSA. The labeled 4T1 cells were then suspended in HBSS-BSA to a final density of 4.0 × 105 cells/mL, and different dosages of TET were added. Cell suspension (100 μL/well) was incubated with HUVECs at 37°C for 30 min. Cultures were carefully washed three times with PBS to remove nonadherent cells. Three random views were photographed in each well at 100x magnification with an inverted fluorescence microscope (Olympus Corporation, Japan). The image was analyzed with Image-Pro Plus 6 software (Media Cybernetics, USA).

2.7. Cell Migration Assay

A wound-healing model was used for evaluation of cell migration ability [15]. Cells treated with 0.1% DMSO were used as the vehicle control. Three random views along the scraped line were photographed in each well at 100x magnification before and after 10 h drug treatment with an inverted fluorescence microscope. The image was analyzed with Image-Pro Plus 6 software. Average scraped width of each well was measured and compared with control.

2.8. Boyden Chamber Transwell Cell Invasion Assay

Cell invasive ability was measured on a transwell system with a polycarbonate membrane (8 μm pores) as previously described in [15]. The upper and lower sides of the membrane were precoated with 1 : 30 (v/v) and 1 : 100 (v/v) matrigel, respectively. The iHUVECs (50,000 cells) were seeded into culture inserts. Low-serum medium containing different concentrations of TET was added into the plate wells. After 12 h, the inserts were washed with PBS; upper surface cells were removed by cotton swabs and the lower side was fixed in 3.7% paraformaldehyde. The invasive cells were then stained with propidium iodide (PI) and mounted on microscope slides. Images were captured at 200x magnification with an inverted fluorescence microscope. Invasive cells were quantified by Image-Pro Plus 6 software. The number of migrate cells per fields was determined by averaging nine randomly counted fields.

2.9. Tube Formation Assay

The effects of the drugs on HUVEC differentiation were examined by their in vitro tube formation ability on matrigel [15]. HUVECs were harvested and diluted to 2 × 105 cell/mL in low-serum medium (0.5% FBS) containing 20 ng/mL Vascular Endothelial Growth Factor (VEGF) and different concentrations of drugs. The cells were then seeded onto 1 : 1 matrigel (v/v) coated 24-well plates at 37°C for 8 h. Cells treated with 0.1% DMSO were used as the vehicle control. The branch points of the capillary-like tubes were counted under light microscopy (100x field).

2.10. Cell Cycle Analysis by Flow Cytometry

Flow cytometry was used for quantitatively detecting the cell-cycle distribution [16]. Cells (1 × 105/well) were plated into 6-well plates 1 day before treatment with TET at various concentrations. After treatment for 24 and 48 h, cells were harvested, washed with PBS, fixed in cold 3.7% paraformaldehyde overnight at 4°C for at least 2 h, and stained with 50 ng/mL PI in the presence of 200 μg/mL RNase A by incubation at 37°C for at least 30 min. The stained cells were analyzed by flow cytometry (Becton-Dickinson). The red fluorescence (PE) representing the DNA content was collected through a 585 nm filter. Data were analyzed using Mod Fit LT 3.0 software.

2.11. Protein Extraction and Western Blotting Analysis

Western blotting was performed as previously described in [17]. Briefly, cells were collected and lysed in RAPI buffer. After treatment on ice for 30 min, cell lysates were clarified by centrifugation at 11,419 ×g for 20 min at 4°C to remove cell debris and the protein content was measured using a BCA protein assay kit (Beyotime, Jiangsu, China). Cleared total cell lysate was denatured by boiling, and aliquots of the lysates were loaded onto a 10% gradient SDS-PAGE. After electrophoretic separation, proteins were transferred to an Immobilon-P membrane. Membrane was blocked with SuperBlock Blocking Buffer and probed with the primary antibody, anti-NF-κB (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-ERK1/2, and p-ERK1/2 (Cell Signaling Technology, Vancouver, Canada), followed by incubation with a secondary antibody conjugated with biotin. Then the PVDF membrane was incubated with streptavidin HRP. The proteins of interest were detected by using SuperSignal West Pico Chemiluminescent Substrate kit.

2.12. Gelatin Zymography

Gelatin zymography was performed on 7.5% polyacrylamide gels containing 0.1% gelatin as previously described in [15]. Cells were treated as indicated in 0.5% FBS RPMI1640 (containing 20 ng/mL VEGF) for 24 h. The cell culture medium was then centrifuged at 350 ×g for 4 min at 4°C, and the total protein of the supernatant was normalized with BCA protein assay kit. The supernatant was mixed with 5x nonreducing sample buffer and loaded onto 10-well gels (20 μL/sample), and electrophoresis was performed at 100 V for 1.25 h. After electrophoresis, the gel was rinsed with 1x renaturing buffer for 1.5 h at room temperature. The buffer was then changed to 1x developing buffer and incubated for 48 h at 37°C. Gelatin gel was stained with Coomassie blue and then destained with 10% acetic acid. The unstained bands correspond to the areas of gelatin digestion.

2.13. 4T1 Tumor Bearing Mice Model

Female BALB/c mice (4 weeks old, 18–20 g, 10 mice per group) were used. Subconfluent 4T1-Luc cells were harvested and resuspended in PBS to a final density of 1 × 107 cells/mL. Before injection, cells were resuspended in PBS and analyzed by 0.4% trypan blue exclusion assay (viable cells, >90%). For cancer cell injection, approximately 5 × 105 4T1-Luc cells in 100 μL of PBS were injected into the mammary fat pad (MFP) of each mouse using 27 gauge needles [18]. At 48 h after tumor cell injection, TET was administered at 10 mg/kg body weight to mice once every 2 days orally, and Dox was administered by intraperitoneal injection at 1 mg/kg/2 days to mice as a positive control.

2.14. Xenogen Bioluminescence Imaging

Small animal whole-body optical imaging was carried out as described previously in [9]. In brief, mice were anesthetized with isoflurane attached to a nose-cone mask equipped with Xenogen IVIS 200 imaging system (Caliper Life Sciences, Hopkinton, MA, USA) and subjected to imaging weekly after MFP injection.

For imaging, mice were injected intraperitoneally with D-luciferin sodium salt (Gold Biotechnology, St. Louis, MO, USA) at 100 mg/kg body weight in 0.1 mL of sterile PBS. Acquired images were obtained by superimposing the emitted light over the grayscale photographs of the animal. Quantitative analysis was done with Xenogen's Living Image V2.50.1 software as described previously in [14]. Animals were taken in vivo images for both untreated and treated groups and sacrificed after 4 weeks. Tumor, lung, and vascular samples were retrieved for histological examination.

2.15. High-Resolution Laser Doppler Perfusion Imaging

Microvascular blood flow was assessed by laser Doppler with a moorFLPI V2.1 software (Moor instruments Ltd, UK) [19, 20]. Mouse hair was carefully removed and mice were anesthetized with isoflurane attached to a nose-cone mask. With a distance of 10 cm between the scanner and the skin surface, three examined areas (1.4∗1.4 cm) were chosen so that tumor (Flux 1), adjacent healthy skin around tumor (Flux 2), and the heart of mice (Flux 3) were covered. The laser beam is reflected by the erythrocytes, which allows recording of the returning signal by a detector positioned in the scanner head and thus conversion to an electrical signal, proportional to the tissue perfusion. The underlying intensity of perfusion values is expressed on a scale of different colours extending from blue (low perfusion values) over green and yellow to red (highest perfusion values). The related perfusion values were calculated as follows: perfusion rate (tumor) = F1/F3∗100%; perfusion rate (vascular) = F2/F3∗100%.

2.16. Histological Evaluation and Immunohistochemical Staining

Retrieved tumor tissues were fixed in 10% formalin and embedded in paraffin. Serial sections of the embedded specimens were stained with hematoxylin and eosin. For immunohistochemical staining, slides were deparaffinized and then rehydrated in a graduated fashion [21]. The deparaffinized slides were subjected to antigen retrieval and probed with anti-ICAM-1, anti-HIF-1α, anti-integrin β5, anti-ESM-1, or anti-VEGF antibody (Santa Cruz Biotechnology) or isotype IgG control, followed by incubation with biotin secondary antibodies and streptavidin-horseradish peroxidase. The presence of the expected protein was visualized by DAB staining and examined under a microscope. Stains without the primary antibody were used as negative controls.

2.17. Statistical Analysis

Data were expressed as mean ± S.D. Statistical significances between vehicle group versus drug treatment groups were determined by one-way analysis of variance. The IC50 of the TET was calculated by SPSS software. A value of P < 0.05 was considered to be statistically significant.

3. Results

3.1. TET Exhibits a Significant Growth-Inhibitory Effect in HUVECs

To assess the antiangiogenic property of TET in vitro, we examined the inhibitory effects of TET on cell viability in HUVECs using MTT assay and crystal violet staining. As shown in Figures 1(a) and 1(b), TET (<10 μM) does not have any remarkable effect on HUVEC proliferation. However, TET can significantly inhibit cell viability at a much higher concentration with a half-maximal inhibition at 16.76 μM (by MTT assay) or 29.31 μM (by crystal violet staining assay). To examine the possible mechanism behind TET's inhibition effect on HUVEC's proliferation, we performed cell cycle analysis by FACS, and the result revealed that when HUVECs were treated with TET for 24 h, TET in 10 μM induced a depletion of cells in the G2-M phase, from 10.70% to 4.21%, and a concomitant accumulation of cells in S phase, from 34.17% to 38.35%. These data suggested that TET could arrest endothelial cell proliferation. Furthermore, we examined the effects of TET on NF-κB, ERK1/2, and p-ERK1/2 expressions, and the results suggested that the inhibition of TET in HUVECs was related to the upregulation of NF-κB and suppression of the phosphorylation of ERK1/2.

Figure 1.

Figure 1

Open in a new tab

Antiproliferative activity of TET in HUVECs. (a) MTT assay. Subconfluent HUVECs were treated with indicated concentrations of TET for 48 h. The cells were then subjected to MTT assay. Each assay condition was done in triplicate (n = 12). (b) Crystal violet assay. HUVECs were treated with TET at the indicated concentrations for 24 h. The cells were subjected to crystal violet assay as described in Section 2. (c) Cell cycle analysis. Cell cycle distribution of HUVECs was analyzed by flowcytometry. Cells were treated with 1 μM TET for 24 h and fixed, and then nuclear DNA was labeled with PI. Histogram display DNA content (x-axis [PE-A]: PI-fluorescence) versus cell counts (y-axis). (d) ERK, p-ERK, and NFκB expressions in HUVECs. The expression of ERK, p-ERK, and NFκB was detected by western blot.

3.2. TET Inhibits Cell Adhesion, Cell Migration, and Cell Invasion of HUVECs

The antiadhesion ability of TET between 4T1 and HUVEC cells was investigated. As a result, TET could suppress the 4T1 and HUVEC adhesion after 30 min treatment (Figure 2(a)). The adhesive cells were decreased to 245 compared with 592 of the control group.

Figure 2.

Figure 2

Open in a new tab

TET inhibits cell adhesion (a), migration (b), and invasion (c) in HUVECs. (a) Cell adhesion assay. HUVECs and 4T1 cells were used to study the cell adhesive ability. **P < 0.01 versus vehicle control. (b) Cell migration assay. Wound-healing model was used for evaluation of cell migration ability. Three random views were photographed along the scraped line in each well at 100x magnification. (c) Cell invasion assay. Cell invasive ability was measured with a transwell system with a polycarbonate membrane (8 μm pores). Images were captured at 200x magnification. (d) Effects of TET on secretion of matrix metalloproteinase-2 (MMP-2). Gelatin zymography was carried out in an SDS-PAGE gel that contained 0.1% gelatin. (e) Effect of TET on ESM-1, ICAM-1, and integrin β5 expressions in tumor tissues. 4T1 tumor bearing mice (top panel) and TET treated tumor bearing mice (bottom panel) (magnification ×400).

Moreover, the VEGF-induced migration of HUVEC cells was significantly suppressed by TET (Figure 2(b)). The migratory distance of HUVEC was significantly decreased by 10 μM TET-contained medium when compared to that of control (P < 0.01). We further tested whether TET could affect chemotactic HUVECs invasion. Using the Boyden chamber transwell assay, we found that when HUVECs were treated with 10 μM TET the numbers of migrated cells across the extracellular matrix protein-coated membranes significantly decreased (Figure 2(c)). Quantitatively, TET was shown to inhibit the numbers of migrated HCT116 cells by approximately 33% over that of the control treatment.

Notably, this inhibitory effect of TET on EC invasion was potentially related to the activity of proteinases (MMPs). To determine the effect of TET on the production of proteinases by HUVEC, culture supernatants were collected and subjected to gelatin zymography. As shown in Figure 2(d), the presence of proteinases (MMPs) digested the gelatin-containing gel and resulted in a clear band at 66 kDa, which was assigned to MMP-2, and TET reduced the gelatinolytic activities of secreted MMP-2 in a dose-dependent manner which corresponded to the inhibition of EC invasion.

In addition, we examined the expression of adhesion and invasion related factors, including integrin β5, ESM-1, and ICAM-1 in vivo. The whole cell staining intensities of integrin β5 and ESM-1 protein were markedly reduced in TET treated tumors, compared with those of the tumors from the control group (Figure 2(e)). On the contrary, the ICAM-1 level in cell was significantly decreased by TET treatment (Figure 2(e), the middle column). These results have demonstrated that TET can effectively inhibit EC adhesion, migration, and invasion through mechanisms of changing the integrin β5, ESM-1, and ICAM-1 expressions.

3.3. TET Inhibits Tubeformation of HUVECs

The effect of TET on the capillary tube formation of ECs was examined. In the absence of VEGF, there was no tube network structure in ECs, whereas the addition of VEGF (20 ng/mL, positive control) induced the formation of tube or cordlike structure and tube network on GFR matrigel. Cultured with TET resulted in shorter and less blunted tubes of ECs than those of VEGF control group (Figure 3(a)). Quantitative measurements showed that TET caused an increase in mean tube branch point formation as compared to VEGF 20 ng/mL group (positive control) (Figure 3(b)). The number of branch was reduced from 15.7 per area in the control group to 3.6 in the group treatment with TET (10 μM) (P < 0.01).

Figure 3.

Figure 3

Open in a new tab

TET inhibits tube formation in HUVECs. The effects of TET on HUVEC differentiation were examined by their in vitro tube formation ability on matrigel. The branch points of the capillary-like tubes were counted under light microscopy (magnification 100x). Each value represents the mean ± S.D. of triplicate samples in each case. **P < 0.01 versus the VEGF-only group.

3.4. TET Inhibits In Vivo Tumor Metastasis in Mouse Breast Tumor Model

We next investigated the in vivo antimetastatic activity of TET using a mouse breast cancer model. Briefly, exponentially growing firefly luciferase-tagged 4T1 cells were injected into the MFP of BALB/c mice, and TET was orally administered (10 mg/kg body weight, once every two days). As shown in Figure 4(a), the Dox and TET treatment groups exhibited significantly decreased Xenogen imaging signal in lung, when compared with the control group four weeks after treatment. At sacrifice, lung metastases were counted. In keeping with the in vitro data, the number of metastasis sites on the lung surface was remarkably decreased by TET, from 6.2 to 2.6 for each mouse, rather than that of Dox treated mouse (Figures 4(b) and 4(c)). Moreover, histological analysis (H & E staining) indicated that TET treatment group exhibited a decreased metastatic tumor mass in lung (Figure 4(d)).

Figure 4.

Figure 4

Open in a new tab

TET inhibits in vivo tumor metastasis in mouse breast cancer model. (a) Bioluminescence imaging of TET treated tumor bearing mice. Firefly luciferase-tagged 4T1 cells were injected into the MFP of BALB/c mice and TET was orally administered (10 mg/kg body weight, once every two days); images were obtained by using IVIS 200 imaging system. Representative Xenogen imaging results at week 4 are shown. (b) TET reduced tumor lung metastasis sites in 4T1 tumor-bearing mice. Picture shows the number of lung metastasis sites on the lung surface for each mouse. The black line shows the average number of metastasis sites for each group. (c) Photograph of pulmonary metastases. Animals were sacrificed after 4 weeks, and the lungs were dissected and photographed. (d) Histological examination of lung samples. Lung tissues sections were stained with H&E stain, and photographs were made under a microscope at a magnification of 400x (T: tumor).

3.5. TET Inhibits In Vivo Angiogenesis in 4T1 Tumor Bearing Mice

The effect of TET on angiogenesis in vivo was also examined in the animal model. As shown in Figure 5(a), four weeks after MFP injection of 4T1 cells into mice, the diameter of the blood vessels in the tumor implanted side is increased, rather than in the other side, but TET could significantly inhibit the increase of the blood vessel diameter from control levels. Consistent with gross observations, solid tumor sections further indicated that TET inhibited neovascularization in tumor mass in vivo, and the average number of new capillaries blood vessel in control group was more than that in TET treated group (Figure 5(b)). These results demonstrated that TET is a potent inhibitor of vascularization and angiogenesis.

Figure 5.

Figure 5

Open in a new tab

TET suppressed tumor angiogenesis in 4T1 tumor bearing mice. (a) The blood vessel diameter of TET treated tumor bearing mice. Picture shows the diameter of blood vessel on mice abdomen for each mouse. (b) Hematoxylin & Eosin staining of tumor tissues. Retrieved tumor samples were fixed, embedded, and subjected to H&E staining. Representative images are shown (magnification, ×400). (c) VEGF and HIF-1α expressions in tumor tissues. Representative staining results are shown: 4T1 tumor-bearing BALB/c mice (top panel) and TET treated mice (bottom panel) (magnification, ×400).

We sought to further investigate the mechanism behind the TET mediated inhibition of angiogenesis activity. As shown in Figure 5(c), we examined the expression of metastatic and angiogenic related proteins, including VEGF and HIF-1α in vivo. The whole cell and nuclear staining intensities of VEGF and HIF-1α were markedly reduced in TET treated tumors, compared with those of the control group.

Lastly, to investigate the blood perfusion change of TET treated tumor bearing mice in tumor surface and skin around tumor area, we took advantage of the laser Doppler perfusion imaging (LDPI) to measure the local perfusion pattern. In the LDPI, the related perfusion of the mice abdomen was decreased after tumor being implanted for 3 weeks, especially the tumor site (Figure 6(a)). The related perfusion of tumor site (Flux 1) in TET group was decreased to 49% lower than that in healthy mice, but with no difference from that of the model group. It suggested that TET could slightly improve the necrosis of tumor 4 weeks after TET administration (Figure 6(b)). However, the related perfusion around tumor site (Flux 2) in TET group was significantly decreased to 82.54% of the model group (P < 0.05), which indicated that TET could markedly decrease the local blood perfusion of tumor 3 weeks after TET administration (Figure 6(c)) and suggested that the tumor angiogenesis was suppressed by TET treatment.

Figure 6.

Figure 6

Open in a new tab

TET inhibits in vivo blood perfusion in 4T1 tumor bearing mice. (a) In vivo LDPI imaging of mice. TET was orally administered (10 mg/kg, once/2 days). With a distance of 10 cm between the scanner and the skin surface, three examined areas (1.4 ∗ 1.4 cm) covered the tumor (Flux 1), adjacent healthy skin around tumor (Flux 2), and the heart of mice (Flux 3). (b and c) Quantitative analysis of microvascular blood perfusion in mice. Related perfusion (Flux 1) = F1/F3∗100%; related perfusion (Flux 2) = F2/F3∗100%. *P < 0.05, **P < 0.01 versus vehicle control.

Taken together, these in vivo results strongly suggest that TET may inhibit the tumor metastasis of breast cancer, possibly by reducing angiogenesis activity and related protein level of breast cancer cells, although further investigation is required.

4. Discussion

The growth and progression of solid tumors are usually limited by the nutrient supply for tumor. Thus, the blockage of microvessels formation and local blood perfusion in tumor might be useful in cancer therapy. Recently, more than 20 antiangiogenic drugs including TNP-470, thalidomide, and endostatin are subjected to different phases of clinical trials. In addition, phytochemicals such as resveratrol, salvianolic acid B, and ginseng saponins were found to exert inhibitory effect on the vascularization [22].

TET has been shown to exhibit anticancer activity in many in vivo models [5, 9, 10]. TET-treated mice (10 mg/kg/day) have fewer metastases than vehicle treated mice, and no acute toxicity or obvious body weight changes [23]. Recent studies showed that TET induces cell cycle arrest and also induces apoptosis in many human cancer cells. In our previous study, we found that inhibition of Wnt/beta-catenin signaling might contribute to the anticancer effects of TET [9]. Nonetheless, it is conceivable that other signaling pathways may also participate in TET's anticancer activity. For example, activation of glycogen synthase kinase 3β (GSK-3β), generation of ROS, activation of p38 mitogen-activated protein kinase (p38 MAPK), and upregulation of p53, p21, p27, and Fas might contribute to the anticancer effects of TET [5, 24–29].

As mentioned previously, TET exhibits significant anticancer activity both in vitro and in vivo, as well as its inhibitory effect on tumor metastasis and angiogenesis. Chen et al. found that TET inhibits the expression of VEGF in glioma cells, has cytotoxic effect on ECV304 HUVECs, and suppresses in vivo angiogenesis in rat [10]. However, the tumor related angiosuppressive property of TET and the molecular mechanism that underlies its activity are not fully understood. In the present study, we used a new LDPI method combined with different angiogenesis assays that are related to proliferation, adhesion, migration, invasion, and tube formation of EC during angiogenic process, to assess the angiosuppressive activity of TET.

Results from the present study demonstrated that TET exerted inhibitory effect on proliferation, adhesion, and capillary tube formation of ECs in a dose-dependent manner. Interestingly, the blood perfusion of the periphery of tumors was significantly reduced by TET treatment. Owing to that the blood perfusion is usually proportional to the body's blood vessels density [30], this result implied that the antimetastasis effect of TET was passably related to the angiosuppressive activity. Similar cases were also observed in the tumor mass of TET treated 4T1-tumor bearing mice. TET was found to effectively suppress the formation of micro vessels in tumor. Furthermore, since tube formation of HUVEC involves EC attachment, migration, and production of ECM degrading enzymes, data in the presented paper indicated that all these steps were interfered by TET and resulted in the attenuation of angiogenesis in vitro and in vivo. Thus, TET may be useful in cancer metastasis by acting as a specific and effective angiosuppressive agent.

We investigated the molecular mechanism underlying the antivascularization activity of TET in breast cancer. TET treated group exhibited a decreased level of VEGF, HIF-1α, ESM-1 and Integrin β5 protein but upregulation of ICAM-1 level. These in vivo results strongly suggest that the inhibitory effect of TET on breast cancer metastasis may be at least in part mediated by inhibiting tumor angiogenesis factors (VEGF and HIF-1α) or regulating adhesion factors (Integrin β5, ESM-1, and ICAM-1), although further investigation is required.

One of the key cell signaling pathways involved in cancer tumorigenesis and metastasis is the hypoxic pathway. As we know, HIF-1α binds to HREs and induces subsequent expression of genes encoding angiogenic factors, such as VEGF and MMPs, leading to angiogenesis [31]. TET could reduce the expression of HIF-1α and then decrease VEGF level and MMPs activity. It is generally believed that VEGF could activate ECs; activated ECs produce many types of enzymes such as matrix metalloproteinases (MMPs) that break down the stroma and ECM proteins [32]. This is the critical step in angiogenesis as well as metastasis. The invasion assay involving the migration of HUVEC through ECM (matrigel) demonstrated that TET could reduce the chemoinvasive ability of EC by reducing the gelatinases activities of the cell culture medium. These noteworthy results indicated that the angiosuppressive effect of TET could be possibly due to the reduction of HIF-1α and/or VEGF expression, as well as MMPs activities.

Recently, several research groups have tried to identify cell adhesion suppressors which could inhibit cancer metastasis by blocking the lodging in blood vessels in the distant organs of disseminated cancer cells or cell clusters [33]. Integrins are important mediators of the malignant phenotype during oncogenic transformation [34]. Breast carcinoma cells express high levels of integrin β5. Bianchi-Smiraglia et al. indicated that cells deficient in integrin β5 have lower migration and proliferative capacities, and ERK signaling pathway plays an important role in the function of integrin β5 in cancer [35]. Our results show that the expression of integrin β5 was decreased by TET treatment and accompanied by a reduced phosphorylated-ERK level. On the other hand, the adhesion factor ESM-1, which could inhibit leukocyte adhesion and migration through the endothelium, was increased in tissue and serum from colorectal cancer patients and ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma [36, 37]. We notified that TET also decreases ESM-1 expression in breast cancer cells, which leads to an inhibition effect of tumor metastasis. Taken together, TET suppressed the integrin β5 and ESM-1 expressions, then depressed the activation of ERK, and regulated cellular proliferation, adhesion, and survival in ECs.

Another important adhesive factor involved in TET's angiosuppressive effect is ICAM-1; several researches showed that ICAM-1 synthesis in ECs is regulated by activation of p38 and NF-κB [38, 39], and ICAM-1 could induce cell adhesion by active ERK, JNK, and p38 pathways [40, 41]. Our IHC results present an upregulation of ICAM-1 in tumor tissue, along with the increasing of NF-κB, and suggested that the promotion effect of TET on NF-κB and ICAM-1 expressions is closely related to its antiangiogenesis effects. Taken together, as shown in Figure 7, our studies indicate that TET is a potential inhibitor of tumor angiogenesis and metastasis by targeting the angiogenesis and metastasis related factors.

Figure 7.

Figure 7

Open in a new tab

The influence of TET on the angiogenesis and metastasis related factors.

Conflict of Interests

The authors declare that there is no conflict of interests.

Authors' Contribution

J.-L. Gao and X. Ji contributed equally to the work.

Acknowledgments

The reported work was supported by China National Natural Science Foundation (no. 81102852, 81228024), the Zhejiang Provincial Key Laboratory Project (no. 2012E10002), and the Innovation Group Project of Zhejiang Chinese Medical University.

References

  • 1.Lu JJ, Bao JL, Chen XP, Huang M, Wang YT. Alkaloids isolated from natural herbs as the anticancer agents. Evidence-Based Complementary and Alternative Medicine. 2012;2012:12 pages. doi: 10.1155/2012/485042.485042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Fu LW, Zhang YM, Liang YJ, Yang XP, Pan QC. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. European Journal of Cancer. 2002;38(3):418–426. doi: 10.1016/s0959-8049(01)00356-2. [DOI] [PubMed] [Google Scholar]
  • 3.Wang TH, Wan JY, Gong X, Li HZ, Cheng Y. Tetrandrine enhances cytotoxicity of cisplatin in human drug-resistant esophageal squamous carcinoma cells by inhibition of multidrug resistance-associated protein 1. Oncology Reports. 2012;28(5):1681–1686. doi: 10.3892/or.2012.1999. [DOI] [PubMed] [Google Scholar]
  • 4.Lai YL, Chen YJ, Wu TY, et al. Induction of apoptosis in human leukemic U937 cells by tetrandrine. Anti-Cancer Drugs. 1998;9(1):77–81. doi: 10.1097/00001813-199801000-00009. [DOI] [PubMed] [Google Scholar]
  • 5.Wu JM, Chen Y, Chen JC, Lin TY, Tseng SH. Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice. Cancer Letters. 2010;287(2):187–195. doi: 10.1016/j.canlet.2009.06.009. [DOI] [PubMed] [Google Scholar]
  • 6.Li X, Su B, Liu R, Wu D, He D. Tetrandrine induces apoptosis and triggers caspase cascade in human bladder cancer cells. Journal of Surgical Research. 2011;166(1):e45–e51. doi: 10.1016/j.jss.2010.10.034. [DOI] [PubMed] [Google Scholar]
  • 7.Ng LT, Chiang LC, Lin YT, Lin CC. Antiproliferative and apoptotic effects of tetrandrine on different human hepatoma cell lines. American Journal of Chinese Medicine. 2006;34(1):125–135. doi: 10.1142/S0192415X06003692. [DOI] [PubMed] [Google Scholar]
  • 8.Lee JH, Kang GH, Kim KC, et al. Tetrandrine-induced cell cycle arrest and apoptosis in A549 human lung carcinoma cells. International Journal of Oncology. 2002;21(6):1239–1244. [PubMed] [Google Scholar]
  • 9.He BC, Gao JL, Zhang BQ, et al. Tetrandrine inhibits Wnt/β-catenin signaling and suppresses tumor growth of human colorectal cancer. Molecular Pharmacology. 2011;79(2):211–219. doi: 10.1124/mol.110.068668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Chen Y, Chen JC, Tseng SH. Tetrandrine suppresses tumor growth and angiogenesis of gliomas in rats. International Journal of Cancer. 2009;124(10):2260–2269. doi: 10.1002/ijc.24208. [DOI] [PubMed] [Google Scholar]
  • 11.Huang E, Bi Y, Jiang W, et al. Conditionally immortalized mouse embryonic fibroblasts retain proliferative activity without compromising multipotent differentiation potential. PLoS One. 2012;7(2) doi: 10.1371/journal.pone.0032428.e32428 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Su Y, Luo X, He BC, et al. Establishment and characterization of a new highly metastatic human osteosarcoma cell line. Clinical and Experimental Metastasis. 2009;26(7):599–610. doi: 10.1007/s10585-009-9259-6. [DOI] [PubMed] [Google Scholar]
  • 13.Gao JL, He TC, Li YB, Wang YT. A traditional chinese medicine formulation consisting of Rhizoma corydalis and Rhizoma curcumae exerts synergistic anti-tumor activity. Oncology Reports. 2009;22(5):1077–1083. doi: 10.3892/or_00000539. [DOI] [PubMed] [Google Scholar]
  • 14.He BC, Gao JL, Luo X, et al. Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/β-catenin signaling. International Journal of Oncology. 2011;38(2):437–445. doi: 10.3892/ijo.2010.858. [DOI] [PubMed] [Google Scholar]
  • 15.Gao JL, Shi JM, Lee SMY, Zhang QW, Wang YT. Angiogenic pathway inhibition of Corydalis yanhusuo and berberine in human umbilical vein endothelial cells. Oncology Research. 2009;17(11-12):519–526. doi: 10.3727/096504009789745575. [DOI] [PubMed] [Google Scholar]
  • 16.Liu YW, Gao JL, Guan J, Qian ZM, Feng K, Li SP. Evaluation of antiproliferative activities and action mechanisms of extracts from two species of ganoderma on tumor cell lines. Journal of Agricultural and Food Chemistry. 2009;57(8):3087–3093. doi: 10.1021/jf900011f. [DOI] [PubMed] [Google Scholar]
  • 17.Gao JL, Shi JM, He K, et al. Yanhusuo extract inhibits metastasis of breast cancer cells by modulating mitogen-activated protein kinase signaling pathways. Oncology Reports. 2008;20(4):819–824. [PubMed] [Google Scholar]
  • 18.DuPré SA, Redelman D, Hunter KW., Jr. The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci. International Journal of Experimental Pathology. 2007;88(5):351–360. doi: 10.1111/j.1365-2613.2007.00539.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Stücker M, Esser M, Hoffmann M, et al. High-resolution laser Doppler perfusion imaging aids in differentiating between benign and malignant melanocytic skin tumours. Acta Dermato-Venereologica. 2002;82(1):25–29. doi: 10.1080/000155502753600849. [DOI] [PubMed] [Google Scholar]
  • 20.Esser D, Oosterink E, op 't Roodt J, et al. Vascular and inflammatory high fat meal responses in young healthy men, a discriminative role of IL-8 observed in a randomized trial. PLoS One. 2013;8(2) doi: 10.1371/journal.pone.0053474.e53474 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Chen L, Jiang W, Huang J, et al. Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation. Journal of Bone and Mineral Research. 2010;25(11):2447–2459. doi: 10.1002/jbmr.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Fan TP, Yeh JC, Leung KW, Yue PYK, Wong RNS. Angiogenesis: from plants to blood vessels. Trends in Pharmacological Sciences. 2006;27(6):297–309. doi: 10.1016/j.tips.2006.04.006. [DOI] [PubMed] [Google Scholar]
  • 23.Chang KH, Liao HF, Chang HH, et al. Inhibitory effect of tetrandrine on pulmonary metastases in CT26 colorectal adenocarcinoma-bearing BALB/c mice. American Journal of Chinese Medicine. 2004;32(6):863–872. doi: 10.1142/S0192415X04002478. [DOI] [PubMed] [Google Scholar]
  • 24.Kuo PL, Lin CC. Tetrandrine-induced cell cycle arrest and apoptosis in Hep G2 cells. Life Sciences. 2003;73(2):243–252. doi: 10.1016/s0024-3205(03)00266-2. [DOI] [PubMed] [Google Scholar]
  • 25.Meng LH, Zhang H, Hayward L, Takemura H, Shao RG, Pommier Y. Tetrandrine induces early G1 arrest in human colon carcinoma cells by down-regulating the activity and inducing the degradation of G 1-S-specific cyclin-dependent kinases and by inducing p53 and p21Cip1. Cancer Research. 2004;64(24):9086–9092. doi: 10.1158/0008-5472.CAN-04-0313. [DOI] [PubMed] [Google Scholar]
  • 26.McCubrey JA, Bäsecke J, Cervello M, Martelli AM, Franklin RA. GSK-3β is a critical mediator of tetrandrine induced cell cycle arrest and cytotoxicity. Cancer Biology and Therapy. 2008;7(7):p. 1079. doi: 10.4161/cbt.7.7.6519. [DOI] [PubMed] [Google Scholar]
  • 27.Chen XL, Ren KH, He HW, Shao RG. Involvement of PI3K/AKT/GSK3beta pathway in tetrandrine-induced G1 arrest and apoptosis. Cancer Biology and Therapy. 2008;7(7):1073–1078. doi: 10.4161/cbt.7.7.6142. [DOI] [PubMed] [Google Scholar]
  • 28.Liu C, Gong K, Mao X, Li W. Tetrandrine induces apoptosis by activating reactive oxygen species and repressing Akt activity in human hepatocellular carcinoma. International Journal of Cancer. 2011;129(6):1519–1531. doi: 10.1002/ijc.25817. [DOI] [PubMed] [Google Scholar]
  • 29.Oh SH, Lee BH. Induction of apoptosis in human hepatoblastoma cells by tetrandrine via caspase-dependent Bid cleavage and cytochrome c release. Biochemical Pharmacology. 2003;66(5):725–731. doi: 10.1016/s0006-2952(03)00397-6. [DOI] [PubMed] [Google Scholar]
  • 30.Stücker M, Springer C, Paech V, Hermes N, Hoffmann M, Altmeyer P. Increased laser Doppler flow in skin tumors corresponds to elevated vessel density and reactive hyperemia. Skin Research and Technology. 2006;12(1):1–6. doi: 10.1111/j.0909-725X.2006.00139.x. [DOI] [PubMed] [Google Scholar]
  • 31.Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. Journal of Applied Physiology. 2000;88(4):1474–1480. doi: 10.1152/jappl.2000.88.4.1474. [DOI] [PubMed] [Google Scholar]
  • 32.Siefert SA, Sarkar R. Matrix metalloproteinases in vascular physiology and disease. Vascular. 2012;20(4):210–216. doi: 10.1258/vasc.2011.201202. [DOI] [PubMed] [Google Scholar]
  • 33.Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proceedings of the Society for Experimental Biology and Medicine. 1999;222(2):124–138. doi: 10.1177/153537029922200203. [DOI] [PubMed] [Google Scholar]
  • 34.Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nature Reviews Cancer. 2002;2(2):91–100. doi: 10.1038/nrc727. [DOI] [PubMed] [Google Scholar]
  • 35.Bianchi-Smiraglia A, Paesante S, Bakin AV. Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene. 2012 doi: 10.1038/onc.2012.320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Kang YH, Ji NY, Han SR, et al. ESM-1 regulates cell growth and metastatic process through activation of NF-κB in colorectal cancer. Cellular Signalling. 2012;24(10):1940–1949. doi: 10.1016/j.cellsig.2012.06.004. [DOI] [PubMed] [Google Scholar]
  • 37.Kang YH, Ji NY, Lee CI, et al. ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma. Amino Acids. 2011;40(3):1003–1013. doi: 10.1007/s00726-010-0729-6. [DOI] [PubMed] [Google Scholar]
  • 38.Guo F, Zhou Z, Dou Y, Tang J, Gao C, Huan J. GEF-H1/RhoA signalling pathway mediates lipopolysaccharide-induced intercellular adhesion molecular-1 expression in endothelial cells via activation of p38 and NF-κB. Cytokine. 2012;57(3):417–428. doi: 10.1016/j.cyto.2011.12.009. [DOI] [PubMed] [Google Scholar]
  • 39.Melotti P, Nicolis E, Tamanini A, Rolfini R, Pavirani A, Cabrini G. Activation of NF-κB mediates ICAM-1 induction in respiratory cells exposed to an adenovirus-derived vector. Gene Therapy. 2001;8(18):1436–1442. doi: 10.1038/sj.gt.3301533. [DOI] [PubMed] [Google Scholar]
  • 40.Tung SY, Chang SF, Chou MH, et al. CXC chemokine ligand 12/stromal cell-derived factor-1 regulates cell adhesion in human colon cancer cells by induction of intercellular adhesion molecule-1. Journal of Biomedical Science. 2012;19(article 91) doi: 10.1186/1423-0127-19-91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Usami Y, Ishida K, Sato S, et al. Intercellular adhesion molecule-1 (ICAM-1) expression correlates with oral cancer progression and induces macrophage/cancer cell adhesion. International Journal of Cancer. 2013 doi: 10.1002/ijc.28066. [DOI] [PubMed] [Google Scholar]

Articles from Evidence-based Complementary and Alternative Medicine : eCAM are provided here courtesy of Wiley

RESOURCES